| Title |
Autophagy Modulation in Disease Therapy: Where Do We Stand?
|
|---|---|
| Published in |
Current Pathobiology Reports, October 2013
|
| DOI | 10.1007/s40139-013-0032-9 |
| Pubmed ID | |
| Authors |
Michael P. Nelson, John J. Shacka |
| Abstract |
Since it was first described more than 50 years ago autophagy has been examined in many contexts, from cell survival to pathogen sequestration and removal. In more recent years our understanding of autophagy has developed sufficiently to allow effective targeted therapeutics to be developed against various diseases. The field of autophagy research is expanding rapidly, demonstrated by increases in both numbers of investigators in the field and the breadth of topics being addressed. Some diseases, such as the many cancers, have come to the fore in autophagy therapeutics research as a better understanding of their underlying mechanisms has surfaced. Numerous treatments are being developed and explored, from creative applications of the classic autophagy modulators chloroquine and rapamycin, to repurposing drugs approved for other treatments, such as astemizole, which is currently in use as an antimalarial and chronic rhinitis treatment. The landscape of autophagy modulation in disease therapy is rapidly changing and this review hopes to provide a cross-section of the current state of the field. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 7 | 41% |
| Other | 2 | 12% |
| Student > Master | 2 | 12% |
| Lecturer | 1 | 6% |
| Lecturer > Senior Lecturer | 1 | 6% |
| Other | 2 | 12% |
| Unknown | 2 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 35% |
| Agricultural and Biological Sciences | 5 | 29% |
| Biochemistry, Genetics and Molecular Biology | 2 | 12% |
| Psychology | 1 | 6% |
| Neuroscience | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 2 | 12% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 January 2014.
All research outputs
#20,707,815
of 23,308,124 outputs
Outputs from Current Pathobiology Reports
#91
of 105 outputs
Outputs of similar age
#182,723
of 208,527 outputs
Outputs of similar age from Current Pathobiology Reports
#3
of 3 outputs
Altmetric has tracked 23,308,124 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 105 research outputs from this source. They receive a mean Attention Score of 3.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 208,527 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.